Vishnu Sunil Jaikumar
Higher Degree by Research Candidate
School of Pharmacy and Biomedical Sciences
College of Health
Vishnu is a final year PhD candidate in the Cell Siganlling Research Group within the Centre for Cancer Biology at the Adelaide University. Supervised by Professor Yeesim Khew-Goodall, Dr Ana Lonic and Professor Michael Samuel, Vishnu's research focuses on understanding the molecular mechanisms underlying chemoresistance in triple-negative breast cancer (TNBC). His project places a particular emphasis on a novel signalling axis involving Protein Kinase C Delta (PKCδ). By employing a variety of cell biology techniques including CRISPR gene editing, flow cytometry and confocal microscopy alongside genetically engineered and xenograft mouse models of TNBC, Vishnu aims to determine the role of the PKCδ molecular switch in modulating the tumour microenvironment.
| Date | Position | Institution name |
|---|---|---|
| 2019 - 2022 | Veterinary Medical Officer | Rajiv Gandhi Centre for Biotechnology |
| 2016 - 2019 | Veterinarian and Research Associate III | Rajiv Gandhi Centre for Biotechnology |
| 2015 - 2016 | Veterinary Surgeon | Animal Birth Control for Dogs (ABCD) Kochi |
| 2014 - 2015 | Research Assistant | Kerala Veterinary and Animal Sciences University |
| 2014 - 2015 | Inpatient Unit Incharge | Kerala Veterinary and Animal Sciences University |
| Date | Type | Title | Institution Name | Country | Amount |
|---|---|---|---|---|---|
| 2024 | Award | FEBS Open Bio Poster Prize | ComBio 2024-Biomolecular Horizons 2024, Melbourne | Australia | - |
| 2012 | Scholarship | Kerala Veterinary and Animal Sciences University Assistantship | Kerala Veterinary and Animal Sciences University | India | - |
| 2012 | Award | Best Clinical Case Presentation Award | Madras Veterinary College, Tamil Nadu Veterinary and Animal Sciences University | India | - |
| Language | Competency |
|---|---|
| Divehi; Dhivehi; Maldivian | Can understand spoken |
| English | Can read, write, speak, understand spoken and peer review |
| Hindi | Can read, speak and understand spoken |
| Malayalam | Can read, write, speak and understand spoken |
| Tamil | Can speak and understand spoken |
| Date | Institution name | Country | Title |
|---|---|---|---|
| 2012 - 2015 | Kerala Veterinary and Animal Sciences University | India | Master of Veterinary Science |
| 2007 - 2012 | Rajiv Gandhi Institute of Veterinary Education and Research | India | Bachelor of Veterinary Science and Animal Husbandry |
| Date | Title | Institution name | Country |
|---|---|---|---|
| — | Certificate in Laboratory Animal Science (FELASA A,B,C,D) | Federation of European Laboratory Animal Science Associations | - |
| — | Certificate in Avian Medicine | QUADAM Institute | - |
| Year | Citation |
|---|---|
| 2026 | Rayginia, T. P., Keerthana, C. K., Aiswarya, S. U., Shifana, S. C., Jannet, S., Varma, S. S., . . . Anto, R. J. (2026). Orphan drug uttroside B impedes MASH progression and HCC development in experimental models. Jhep Reports, 8(2), 16 pages. |
| 2026 | Raj R, R., Datta, N., Krishnan U, S., Shanmugam, G., Louis, J. M., Jeyaram, R. D., . . . Maliekal, T. T. (2026). EPHA2-Ephrin-B1 cis-interaction drives an oncogenic reverse signaling, leading to the recurrence of oral cancer. Cell Communication and Signaling, 24(1), 300. |
| 2026 | Keerthana, C. K., Rayginia, T. P., Kalimuthu, K., Saha, S., Haritha, N. H., Nisthul Areekkara, A., . . . Anto, R. J. (2026). Uttroside B, a US FDA-designated ‘Orphan Drug’, mitigates the development of hepatocellular carcinoma and its pulmonary metastasis via EGFR/ERK-mediated inhibition of SREBP-1 and STAT-3. Cell Death Discovery, 12(1), 250. |
| 2025 | Das, D. J., Jaikumar, V. S., Suryaletha, K., Paul, M., Shankar, A., Nath, S. R., & Thomas, S. (2025). Probiotic Lacticaseibacillus paracasei from human gut microbiome against colistin-resistant Klebsiella pneumoniae: in vitro, in vivo and probiogenomic approaches. Beneficial Microbes, 16(4), 443-463. Scopus2 WoS2 Europe PMC2 |
| 2025 | Patra, D., Varghese, G. R., Jaikumar, V. S., Rajan, A., Krishnan, N., Kuppuswamy, K., . . . Srinivas, P. (2025). Decoding BRCA1 promoter hypermethylation: a new frontier in understanding sporadic breast cancer. Cancer Gene Therapy, 32(12), 1400-1413. Scopus2 WoS2 Europe PMC2 |
| 2024 | Nair, M. G., Mavatkar, A. D., Naidu, C. M., V. P, S., C. E, A., Rajarajan, S., . . . Prabhu, J. S. (2024). Elucidating the Role of MicroRNA-18a in Propelling a Hybrid Epithelial–Mesenchymal Phenotype and Driving Malignant Progression in ER-Negative Breast Cancer. Cells, 13(10), 24 pages. Scopus4 WoS4 Europe PMC3 |
| 2024 | Remadevi, V., Jaikumar, V. S., Vini, R., Krishnendhu, B., Azeez, J. M., Sundaram, S., & Sreeja, S. (2024). Urolithin A, induces apoptosis and autophagy crosstalk in Oral Squamous Cell Carcinoma via mTOR /AKT/ERK1/2 pathway. Phytomedicine, 130, 11 pages. Scopus18 WoS16 Europe PMC13 |
| 2023 | Vini, R., Jaikumar, V. S., Remadevi, V., Ravindran, S., Azeez, J. M., Sasikumar, A., . . . Sreeja, S. (2023). Urolithin A: A promising selective estrogen receptor modulator and 27-hydroxycholesterol attenuator in breast cancer. Phytotherapy Research, 37(10), 4504-4521. Scopus12 WoS10 Europe PMC10 |
| 2023 | Varghese, G. R., Patra, D., Jaikumar, V. S., Rajan, A., Latha, N. R., & Srinivas, P. (2023). βhCG mediates immune suppression through upregulation of CD11b+Gr1+ myeloid derived suppressor cells, CD206+ M2 macrophages, and CD4+FOXP3+ regulatory T-cells in BRCA1 deficient breast cancers. Immunology, 170(2), 270-285. Scopus6 WoS7 Europe PMC5 |
| 2023 | Thankamony, A. P., Ramkomuth, S., Ramesh, S. T., Murali, R., Chakraborty, P., Karthikeyan, N., . . . Nair, R. (2023). Phenotypic heterogeneity drives differential disease outcome in a mouse model of triple negative breast cancer. Frontiers in Oncology, 13, 13 pages. Scopus10 WoS8 Europe PMC8 |
| 2023 | Jayalekshmi, V. S., Jaikumar, V. S., Mehra, P., Thulaseedharan, T., Vinod, V. M., & Ramachandran, S. (2023). Differential expression of lipid metabolic genes in hypercholesterolemic rabbit placenta predisposes the offspring to develop atherosclerosis in early adulthood. Life Sciences, 327, 15 pages. Scopus4 WoS4 Europe PMC3 |
| 2023 | Richard, V., Nair, M. G., Jaikumar, V. S., Jones, S., Prabhu, J. S., & Kerin, M. J. (2023). Cell State Transitions and Phenotypic Heterogeneity in Luminal Breast Cancer Implicating MicroRNAs as Potential Regulators. International Journal of Molecular Sciences, 24(4), 3497. Scopus6 Europe PMC7 |
| 2022 | Wanjale, M. V., Jaikumar, V. S., Sivakumar, K. C., Paul, R. A., James, J., & Kumar, G. S. V. (2022). Supramolecular Hydrogel Based Post-Surgical Implant System for Hydrophobic Drug Delivery Against Glioma Recurrence. International Journal of Nanomedicine, 17, 2203-2224. Scopus27 WoS25 Europe PMC21 |
| 2022 | Riya, P. A., Basu, B., Surya, S., Parvathy, S., Lalitha, S., Jyothi, N. P., . . . James, J. (2022). HES1 promoter activation dynamics reveal the plasticity, stemness and heterogeneity in neuroblastoma cancer stem cells. Journal of Cell Science, 135(22), 16 pages. Scopus17 WoS18 Europe PMC15 |
| 2021 | Mukesh, R. K., Kalam, A. A., Nag, J., Jaikumar, V. S., Kunnakkadan, U., Kumar, N. A., . . . Johnson, J. B. (2021). Chandipura virus induces cell death in cancer cell lines of human origin and promotes tumor regression in vivo. Molecular Therapy Oncolytics, 23, 254-265. Scopus6 WoS6 Europe PMC7 |
| 2020 | Narendrakumar, L., Jaikumar, V. S., Chandrika, S. K., & Thomas, S. (2020). Epidemiological and pathogenic characteristics of Haitian variant V. cholerae circulating in India over a decade (2000–2018). Microbial Pathogenesis, 149, 10 pages. Scopus3 WoS3 Europe PMC3 |
| Year | Citation |
|---|---|
| 2025 | Padmaja, K. P., Mohan, A., Nair, M., Prabhu, J., Shabeer, H., Snijesh, V. P., . . . Maliekal, T. T. (2025). TIF1γ drives oral cancer recurrence by the transcriptional regulation of self-renewal genes, such as <i>HES1</i>. DOI |
| 2024 | Rayginia, T., Keerthana, C., Aiswarya, S., Shifana, S., Jannet, S., Varma, S. S., . . . Anto, R. J. (2024). Uttroside B, a US-FDA-Designated Orphan Drug Against Hepatocellular Carcinoma (HCC), Impedes Non-alcoholic Steatohepatitis (NASH) and NASH -Induced HCC. DOI |
| 2024 | Srinivas, P., Latha, N. R., Jaikumar, V. S., Varghese, G. R., Krithiga, K., Krishnan, N., . . . Patra, D. (2024). Targeting Ezrin Can Impede Transformation of Cancer Associated Fibroblast (Caf) to Metastasis Associated Fibroblasts (Maf) in Brca1 Defective Triple Negative Breast Cancers. DOI |
| 2022 | Patra, D., Varghese, G. R., Jaikumar, V. S., Rajan, A., Krishnan, N., Kuppuswamy, K., . . . Srinivas, P. (2022). BRCA1 Hypermethylation In Sporadic Breast Cancers: Discovering A Novel Pathway To Tumorigenesis Via Coordinate NBR2 Deregulation And TNBC Transformation. DOI |
| 2022 | Thankamony, A., Murali, R., Chakraborty, P., Karthikeyan, N., Varghese, B. A., Jaikumar, V. S., . . . Nair, R. (2022). Phenotypic Heterogeneity Drives Differential Disease Outcome in Triple Negative Breast Cancer. DOI |
| 2022 | Nair, M., Apoorva, D., Chandrakala, M., Snijesh, V. P., Anupama, C. E., Rajarajan, S., . . . Prabhu, J. (2022). Acquisition of hybrid E/M phenotype associated with increased migration, drug resistance and stemness is mediated by reduced miR-18a levels in ER-negative breast cancer. DOI Europe PMC1 |
Connect With Me
External Profiles
